Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062493 | 1.00 | MEN1 (0.56) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| Hydrochloric Acid SCHEMBL10957229 | 0.98 | MEN1 (0.55) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| Hydrochloric Acid SCHEMBL29457654 | 0.98 | MEN1 (0.55) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| Acetic Acid SCHEMBL38655310 | 0.89 | MEN1 (0.51) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL1520386 | 0.80 | HTR2C (0.62) | CYP3A4HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL18071812 | 0.80 | HTR2C (0.62) | CYP3A4HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL25111788 | 0.75 | MEN1 (0.56) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL329626 | 0.75 | HTR2C (0.67) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL31159134 | 0.75 | HTR2C (0.67) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL2026301 | 0.75 | MEN1 (0.56) | MEN1CYP3A4CYP2D6KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009005459-A1 | PHENYL-1,2, 3,4-TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A PAIN DISORDER | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | claimed |
| CN-101119969-A | Aryl and heteroaryl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine, and serotonin | AMR TECHNOLOGY INC (US) | 2008-02-06 | — | — | CN | claimed |
| EP-0214905-A2 | Tetrahydroisoquinoline derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1987-03-18 | — | — | EP | claimed |
| EP-0058932-B1 | 4-ARYLOXY-1,2,3,4-TETRAHYDROISOQUINOLINES, AND INTERMEDIATES, A PROCESS FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-07-17 | — | — | EP | claimed |
| EP-0058932-A2 | 4-Aryloxy-1,2,3,4-tetrahydroisoquinolines, and intermediates, a process for preparing the same, a pharmaceutical composition containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1982-09-01 | — | — | EP | claimed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076620-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-4410699-A | ANALGESICS, ANTICONVULSANTS, HYPOTENSIVE AGENTS, DIURETICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4410699-A | ANALGESICS, ANTICONVULSANTS, HYPOTENSIVE AGENTS, DIURETICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4375471-A | ANTICONVULSANTS, ANALGERSICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-03-01 | — | — | US | disclosed |
| EP-0071919-A2 | Spiro(benzofuran-2(3H),4'(2'H)-isoquinoline)s, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-02-16 | — | — | EP | disclosed |
| US-4374137-A | ANALGESIC, ANTICONVULSANT, HYPOTENSIVE, DIURETIC | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-02-15 | — | — | US | disclosed |
| EP-0058932-A2 | 4-Aryloxy-1,2,3,4-tetrahydroisoquinolines, and intermediates, a process for preparing the same, a pharmaceutical composition containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4028363-A | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 1977-06-07 | — | — | US | disclosed |
| US-4028363-A | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | MEN1 4581/4885CYP3A4 4020/4885CYP2D6 4377/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | MEN1 4388/4885CYP3A4 1177/4885CYP2D6 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.